
|Videos|October 13, 2022
Treatment Approaches for Castration-Sensitive Prostate Cancer with Low Volume Metastatic Disease
Author(s)Sheela Tejwani, MD
An expert oncologist describes her approaches to treating patients with castration-sensitive prostate cancer and low-volume metastatic disease.
Advertisement
Advertisement
Related to this article

Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST
4
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
5
